{
  "symbol": "CTOR",
  "company_name": "Citius Oncology Inc",
  "ir_website": "https://citiuspharma.com/investors/default.aspx",
  "structured_data": [
    {
      "section_name": "Press Releases & Media",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://citiuspharma.com/investors/news-media/news/default.aspx",
          "content": "Citius Pharmaceuticals, Inc. - Investors - Press Releases & Media - Press Releases \n\n[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Press Releases\n\nSelecting a year value will change the news content\n\nSelect Year:\n\nLoading\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Media",
          "url": "https://citiuspharma.com/investors/news-media/media/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Media\n\n##  Media Coverage\n\nSelecting a year value will change the news content\n\nSelect Year:\n\nLoading\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Events",
          "url": "https://citiuspharma.com/investors/events-and-presentations/events/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Events\n\n##  Upcoming Events\n\n##  Archived Events\n\nSelecting a year value will change the event content\n\nSelect year:\n\nLoading...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Corporate Presentation",
          "url": "https://citiuspharma.com/investors/events-and-presentations/presentations/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Corporate Presentation\n\n##  Featured Presentation\n\nLoading ...\n\n##  Fact Sheet\n\nLoading ...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Analyst Coverage",
          "url": "https://citiuspharma.com/investors/stock-information/analyst-coverage/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Analyst Coverage\n\nAnalyst Coverage Table **Firm** | **Analyst**  \n---|---  \nE.F. Hutton| Jason Kolbert  \nH.C. Wainwright| Vernon Bernadino  \nMaxim Group| Michael OkunewitchJason McCarthy, Ph.D.  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Stock Quote",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-quote",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\nLoading ...\n\n## Stock Chart\n\n## Historical Stock Quote\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        },
        {
          "title": "Stock Chart",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-chart",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\n### Nasdaq: CTXR\n\nPrice\n\n$3.32\n\nVolume\n\n180,476\n\nChange\n\n-0.28\n\n% Change\n\n-7.78%\n\nToday's Open\n\n$3.49\n\nPrevious Close\n\n$3.60\n\nIntraday High\n\n$3.60\n\nIntraday Low\n\n$3.26\n\n52 Week High\n\n$26.75\n\n52 Week Low\n\n$2.55\n\nPricing delayed by 20 minutes. Last Updated 11/29/2024 1:00 PM\n\n## Stock Chart\n\n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec123456789101112131415161718192021222324252627282930Look Up\n\n### Stock Quote: Nasdaq: CTXR\n\nLoading historical data...\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        },
        {
          "title": "Historical Stock Quote",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#stock-historical",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\n### Nasdaq: CTXR\n\nPrice\n\n$3.32\n\nVolume\n\n180,476\n\nChange\n\n-0.28\n\n% Change\n\n-7.78%\n\nToday's Open\n\n$3.49\n\nPrevious Close\n\n$3.60\n\nIntraday High\n\n$3.60\n\nIntraday Low\n\n$3.26\n\n52 Week High\n\n$26.75\n\n52 Week Low\n\n$2.55\n\nPricing delayed by 20 minutes. Last Updated 11/29/2024 1:00 PM\n\n## Stock Chart\n\n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec123456789101112131415161718192021222324252627282930Look Up\n\n### Stock Quote: Nasdaq: CTXR\n\nLoading historical data...\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        },
        {
          "title": "Investment Calculator",
          "url": "https://citiuspharma.com/investors/stock-information/default.aspx#calculator",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Stock Information\n\n## Stock Quote\n\nLoading ...\n\n## Stock Chart\n\n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec123456789101112131415161718192021222324252627282930Look Up\n\n### Stock Quote: Nasdaq: CTXR\n\nLoading historical data...\n\n## Investment Calculator\n\nAmount ($)\n\nStart Date: Investment calculator calendar\n\nEnd Date: Investment calculator calendar\n\n### Compare to:\n\nS&P 500\n\nNasdaq 100\n\nDow 30\n\nOther\n\nReinvest Dividends\n\nCalculate Investment\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n\nPrevNext\n\nJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovember200420052006200720082009201020112012201320142015201620172018201920202021202220232024\n\nS| M| T| W| T| F| S  \n---|---|---|---|---|---|---  \n[1](#)| [2](#)  \n[3](#)| [4](#)| [5](#)| [6](#)| [7](#)| [8](#)| [9](#)  \n[10](#)| [11](#)| [12](#)| [13](#)| [14](#)| [15](#)| [16](#)  \n[17](#)| [18](#)| [19](#)| [20](#)| [21](#)| [22](#)| [23](#)  \n[24](#)| [25](#)| [26](#)| [27](#)| [28](#)| [29](#)| [30](#)  \n  \nTodayClose\n"
        }
      ]
    },
    {
      "section_name": "Financials & SEC Filings",
      "links": [
        {
          "title": "Quarterly Results",
          "url": "https://citiuspharma.com/investors/financials/quarterly-results/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Quarterly Results\n\n## Financial Summary Table\n\nshowing 1-3 of 14\n\nFinancial summary table containing documents grouped by year, quarter and typeFiscal Year  \n---  \n2024|  2023|  2022|  2021|  2020|  2019|  2018|  2017|  2016|  2015|  2014|  2013|  2012|  2011  \nPress Release| [Q1 ](https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2024-Financial-Results-and-Provides-Business-Update/default.aspx)[Q2 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2023-Financial-Results-and-Provides-Business-Update)[Q2 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update)[Q3 ](https://citiuspharma.com/investors/news-media/news/release-details/2023/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update/default.aspx)[Q4 ](https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2023-Financial-Results-and-Provides-Business-Update/default.aspx)| [Q1 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-First-Quarter-2022-Financial-Results-and-Provides-Business-Update)[Q2 ](https://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update/default.aspx)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update)[Q4 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2022-Financial-Results-and-Provides-Business-Update)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[Q2 ](/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Second-Fiscal-Quarter-2021-Financial-Results-and-Provides-General-Business-Update-2021-5-13-2021-5-13/default.aspx)[Q3 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Third-Fiscal-Quarter-2021-Financial-Results-and-Provides-General-Business-Update)[Q4 (opens in new window)](http://citiuspharma.com/investors/news-media/news/release-details/2021/Citius-Pharmaceuticals-Inc.-Reports-Fiscal-Full-Year-2021-Financial-Results-and-Provides-Business-Update)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)| [ Q1 Q1 Press Release not available](javascript:void\\(0\\);)[ Q2 Q2 Press Release not available](javascript:void\\(0\\);)[ Q3 Q3 Press Release not available](javascript:void\\(0\\);)[ Q4 Q4 Press Release not available](javascript:void\\(0\\);)  \nFinancial Statement| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q1/fb696874-68da-4a59-ae30-e05dd44650ac.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q2/27eb5e9b-423e-4766-af27-75236283b8f5.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2024/q3/406ac888-5c0a-4f17-a6e5-7c492704626d.pdf)[ Q4 Q4 Financial Statement not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q1/2b153e8b-ed0b-4e0d-a96c-2c3d5924f178.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q2/b26e7090-a86a-433a-8ce4-1dac0bd100f5.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/q2/8d0aefb8-ce89-4d3d-a270-96b8c36d4ee5.pdf)[ Q4 Q4 Financial Statement not available](javascript:void\\(0\\);)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q1/478d267f-353b-4b1f-bc92-a36378566613.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q2/7ba9e69d-de91-4133-a0e3-c99f458a0b48.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q3/4b6eefd8-47f6-4fdf-8614-7c08364dcf07.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q1/0001213900-21-008453.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q2/0001213900-21-025920.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q3/0001213900-21-042071.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/q4/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q1/0001213900-20-003577.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q2/0001213900-20-012286.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/q3/0001213900-20-022331.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q1/0001213900-19-002563.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q2/0001213900-19-008833.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/q3/0001213900-19-015793.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q1/0001213900-18-001880.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q2/0001213900-18-005952.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/q3/0001213900-18-011072.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q1/0001477932-17-000773.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q2/0001477932-17-002308.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/q3/0001477932-17-003946.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q1/0001477932-16-008554.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q2/0001477932-16-010425.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/q3/0001477932-16-011894.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q1/0001477932-15-001225.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q2/0001477932-15-003063.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/q3/0001477932-15-005025.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q1/0001185185-14-000338.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q2/0001185185-14-001283.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/q3/0001185185-14-002170.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q1/0001185185-13-000267.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q2/0001185185-13-001079.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/q3/0001185185-13-001832.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)| [Q1 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q1/0001185185-12-000229.pdf)[Q2 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q2/0001185185-12-000973.pdf)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/q3/0001185185-12-001826.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)| [ Q1 Q1 Financial Statement not available](javascript:void\\(0\\);)[ Q2 Q2 Financial Statement not available](javascript:void\\(0\\);)[Q3 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/q3/0001019687-11-002825.pdf)[Q4 (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)  \nAnnual Report| [ AR AR Annual Report not available](javascript:void\\(0\\);)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2021/ar/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)| [PDF (opens in new window)](https://s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)[ AR AR Annual Report not available](javascript:void\\(0\\);)  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Annual Reports",
          "url": "https://citiuspharma.com/investors/financials/annual-reports/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Annual Reports\n\n2023 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2023/ar/a038a3e4-64d9-4c88-a943-707e5006587c.pdf)\n\nArchived Reports\n\n2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011\n\n2022 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2022/q4/63bf251a-c552-4de7-84a9-a2aba6b6788e.pdf)\n\n2021 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2021/ar/f10k2021_citiuspharmaEDGAR8_Bannerless.pdf)\n\n2020 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2020/ar/0001213900-20-043004.pdf)\n\n2019 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2019/ar/0001213900-19-026259.pdf)\n\n2018 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2018/ar/0001213900-18-017214.pdf)\n\n2017 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2017/ar/0001213900-17-013191.pdf)\n\n2016 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2016/ar/0001477932-16-014315.pdf)\n\n2015 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617@2x.png)\n\n[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2015/ar/0001477932-15-007617.pdf)\n\n2014 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353@2x.png)\n\n[10-KT](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001477932-14-007353.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2014/ar/0001185185-14-000261.pdf)\n\n2013 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-002725.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2013/ar/0001185185-13-000090.pdf)\n\n2012 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-002886.pdf)[10-K](//s28.q4cdn.com/169506891/files/doc_financials/2012/ar/0001185185-12-000067.pdf)\n\n2011 Annual Report\n\n![](//s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313@2x.png)\n\n[NT 10-K](//s28.q4cdn.com/169506891/files/doc_financials/2011/ar/0001185185-11-002313.pdf)\n\nView More\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "SEC Filings",
          "url": "https://citiuspharma.com/investors/financials/sec-filings/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# SEC Filings\n\nSelecting the value will change the page content\n\nSelect Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other\n\nDate Filing Type Filing Description Download / View\n\nLoading ...\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Governance",
      "links": [
        {
          "title": "Management Team",
          "url": "https://citiuspharma.com/about/management-team/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Management Team\n\n#### \n\nLeonard MazurCo-Founder, CEO and Chairman of the Board of Directors\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Leonard-Mazur.jpg)\n\nMr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable success in founding and building multiple healthcare companies and creating value and returns for investors throughout his five-decade career. Mr. Mazur was the co-founder and Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He was previously the co-founder and Vice Chairman of Akrimax Pharmaceuticals, LLC, which specialized in cardiovascular and general pharmaceutical products. From 2005 to 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC, a specialty pharmaceutical company producing prescription dermatological drugs. As founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., a dermatological products company that marketed its products through dermatologists’ offices and co-promoted products for major pharmaceutical companies, he successfully negotiated the company’s sale in 2003 to Pierre Fabre, a leading global pharmaceutical company. Mr. Mazur has extensive sales, marketing, and business development experience from previous tenures at Medicis Pharmaceutical Corporation, ICN Pharmaceuticals, Inc., Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.\n\nMr. Mazur was born in Ansbach, Germany, and emigrated with his family to the U.S. at an early age. Mr. Mazur served in the U.S. Marine Corps Reserve while studying at Temple University for his undergraduate degree. He earned his MBA from Temple University’s Fox School of Business in 1975.\n\nMr. Mazur is a recipient of the Ellis Island Medal of Honor presented annually to those who immigrated to the United States during the Ellis Island era and have shown an outstanding commitment to serving the United States either professionally, culturally, or civically. \n\n#### \n\nMyron HolubiakCo-Founder, Executive Vice Chairman\n\n![](https://s28.q4cdn.com/169506891/files/images/board/Myron-Holubiak.jpg)\n\nMr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc., a premier multinational research-based pharmaceutical company, from 1998 to 2001. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. Before being named President, he held sales and marketing positions at Roche during his 19-year tenure. Earlier, Mr. Holubiak founded Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). He was also a director of Bioscrip, Inc., a national home infusion company, serving as its Chairman of the Board from 2012 through 2016. Since 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. and its predecessor, Ventrus Biosciences, Inc., and is a trustee of the Academy of Managed Care Pharmacy Foundation. \n\nMr. Holubiak received a BS in molecular biology and biophysics from the University of Pittsburgh. He received advanced business training from Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.\n\n#### \n\nJaime BartushakChief Financial Officer & Chief Business Officer\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Jaime-Bartushak.jpg)\n\nMr. Bartushak is an experienced finance and operations professional for early-stage pharmaceutical companies, and has over 20 years of corporate finance, business development, M&A, restructuring, capital formation, and strategic planning expertise. Mr. Bartushak is a founder of Leonard-Meron Biosciences, and, as CFO, was instrumental in obtaining initial investment capital for its start-up in 2014. Earlier, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc., and before that, he led the financial efforts for the successful sale of Triax Pharmaceuticals to PreCision Dermatology.\n\nMr. Bartushak holds a Master of Science and BS from the New Jersey Institute of Technology.\n\n#### \n\nMyron S. Czuczman, MDChief Medical Officer and EVP\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Myron-S.-Czuczman.jpg)\n\nDr. Czuczman is an experienced physician-scientist, academic oncologist, and pharma executive with decades of experience in strategic design, implementation, and oversight for the global development of novel therapeutics for hematologic malignancies. Dr. Czuczman joined Citius from Celgene where he was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL. In this role, Dr. Czuczman managed a global team of physicians and scientists responsible for cross-functional development of compounds from proof-of-principle to worldwide registration. Prior to his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center. \n\nDr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City.\n\n#### \n\nGary F. TalaricoEVP, Operations\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Gary-F.-Talarico.jpg)\n\nMr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Most recently, he was a founder, partner and Executive Vice President of Leonard-Meron Biosciences, Inc.; he was instrumental in acquiring its lead product. Previously, Mr. Talarico served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, he was Executive Vice President of Business Development for Ventiv Health. His earlier experience included tenures as Vice President of Sales for Medicis Pharmaceutical Corporation at its start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Mr. Talarico is a graduate of Lewis University.\n\n#### \n\nJay WadekarSVP, Business Strategy\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Jay-Wadekar.jpg)\n\nMr. Wadekar has been associated with Citius since its inception. Prior to Citius, he lead the clinical program at Ischemix, Inc., a company developing novel therapies for cardiovascular conditions. Mr. Wadekar has more than thirty years of experience in areas of finance, corporate strategy, sales and senior leadership in the healthcare field. Mr. Wadekar has held numerous executive level positions throughout his career in biotechnology and pharmaceutical industries including Chairman and CEO of Able Laboratories, Inc. Most recently he served as a strategic advisor to Camber Pharmaceuticals, Inc. where he was instrumental in building the executive team and establishing Camber’s Sales Operations systems.\n\n#### \n\nKelly Creighton, PhDEVP, Chemistry, Manufacturing and Controls\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Kelly-Creighton288.jpg)\n\nKelly joined Citius from Clinipace Worldwide, a leading global contract research organization, where he served as Vice President of Regulatory and Strategic Development. As a senior-level regulatory affairs and quality assurance expert with nearly two decades of experience in biopharmaceuticals, pharmaceuticals, advanced therapies, including gene and cellular therapies, and combination products, he has provided comprehensive regulatory strategy assessments, development plans and regulatory dossiers for programs across a wide range of therapeutic areas. As head of a global CMC regulatory activities for investigational products, he has led teams throughout North America, Europe and the Asia Pacific region overseeing submissions and negotiations with regulatory authorities, as well as biosafety and environmental agencies in each of these regions. Kelly has directed the implementation of multiple CMC development plans including: contract manufacturing organization selection, product manufacturing, analytical development, product characterization, specification establishment, container closure systems and stability requirements. Additionally, his substantial product development experience extends to biologics/biosimilars, small molecule, gene and cellular therapies, cancer immunotherapies, live oncolytic biotherapeutics, and microbiome therapies. Twenty products for which he prepared regulatory marketing applications (NDAs, ANDAs, and BLAs) were approved in the US and EU. Additionally, he has performed internal and external quality assurance audits for drug products, drug substance, and tissue and cell therapy products. Kelly earned his BS from New Mexico State University and his MSc and PhD from the University of Nebraska. \n\n#### \n\nCatherine Kessler, MSEVP, Regulatory Affairs\n\n![](https://s28.q4cdn.com/169506891/files/CK-Pic-2022-003-\\(3\\).jpg)\n\nCatherine Kessler joined Citius with more than 25 years of experience in the life sciences industry. For over 20 years, Ms. Kessler focused on regulatory affairs supporting early and late-stage product development in multiple therapeutic areas. Ms. Kesesler’s expertise extends to regulatory research and surveillance, developing regulatory paths to market for unique products, and effectively engaging health authorities through complex stages of product clinical development. She has supported development, U.S. marketing approvals, and/or post-marketing approvals of multiple FDA-approved products including: Mektovi®, Koselugo™, Tukysa®, Enbrel®, Remicade®, Humate-P®, Mononine®, Albuminar®, and a broad range of investigational products (small molecules, chemical solutions, medical devices, protein therapeutics, cellular therapies; oral capsules/tablets/drinks, intravenous injections, intrauterine devices, biologic/device combination products) in various phases of clinical development (pre-Phase 1 through Phase 3). These products have spanned numerous therapeutic indications including oncology (solid and liquid tumors), cardiovascular disease, inflammatory disease, and reproductive women’s health. \n\nMs. Kessler is a seasoned pharmaceutical executive who has held positions of increasing responsibility at SmithKline Beecham Pharmaceuticals, Centocor, Aventis Behring, Amgen, Array BioPharma, Clinipace Worldwide, and Imvax. She received a Master of Science in Quality Assurance and Regulatory Affairs from Temple University and a Bachelor of Science in Biochemistry from the University of Delaware. \n\n#### \n\nNikolas BurlewEVP, Quality Assurance\n\n![](https://s28.q4cdn.com/169506891/files/images/management/2023/Nikolas-Burlew-Headshot-Dec-2022-\\(002\\)-crop.png)\n\nNik Burlew joined Citius from Clovis Oncology, Inc. where he served as Vice President of Quality Assurance. Prior to joining Clovis, Nik was the Executive Vice President of Regulatory and Strategic Development at Clinipace where he spent 15 years providing quality and CMC consulting counsel to clinical and commercial biologics and pharmaceutical companies. As a senior-level quality assurance expert with over three decades of experience in biopharmaceuticals, pharmaceuticals, advanced therapies, including gene and cellular therapies, natural products, live-biotherapeutics and combination products, Nik has provided quality and development plans for programs across a wide range of therapeutic areas. As the global head of QA for commercial and clinical stage companies, he has led teams throughout North America, Europe and Asia Pacific overseeing the application of quality programs in Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Laboratory Practice (GLP) and Good Distribution Practice (GDP). Nik has successfully engaged with Health Authorities around the world in a variety of GxP inspections and negotiations including: FDA, EMA, MHRA, HPRA, BfArM, ANVISA, AEMPS, AIFA, PMDA, and Swissmedic. Additionally, his substantial product development experience extends to biologics, small molecules, natural products, gene and cellular therapies, cancer immunotherapies, live oncolytic biotherapeutics, and the microbiome. Mr. Burlew earned his B.S. in environmental, population and organismic biology from the University of Colorado Boulder. \n\n#### \n\nAlan Lader, PhDSVP, Head of Clinical Operations and Quality Assurance\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Alan-Lader.jpg)\n\nDr. Lader has over 30 years of experience in medical research. Prior to joining Citius, Dr. Lader was the Director of Clinical Operations for Ischemix, Inc. Previously, Dr. Lader served as an Instructor in Medicine at Harvard Medical School and Brigham and Women’s Hospital. He taught Integrated Human Physiology, and was Principal Investigator for NIH-funded studies in mechanisms of lung cancer metastasis. Dr. Lader has authored more than 20 publications in peer-reviewed journals, and has presented more than 25 abstracts at scientific meetings. Dr. Lader’s career began at Hartford Hospital where he supported clinical research in cardiovascular medicine. He earned his Ph.D. from the University of South Carolina School of Medicine, M.S. from Rensselaer Polytechnic Institute in Biomedical Engineering and his B.S. degree in Bioengineering from Syracuse University.\n\n#### \n\nIlanit AllenVP, Investor Relations\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Ilanit-Allen.jpg)\n\nMs. Allen has more than 20 years of experience in corporate communications, investor relations, strategy and investment banking. Ms. Allen has provided investor relations counsel to more than two dozen private and public life science companies. Previously, she advised executives across a broad spectrum of industries and growth stages, including technology startups and Fortune 500 financial institutions. Ilanit began her career as an investment banking analyst at SG Cowen with a focus on mergers and acquisitions. Ms. Allen holds an MBA from Harvard Business School, a Bachelor of Science degree in Finance from The Wharton School, and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.\n\n#### \n\nJohn WestmanVP, Project Management\n\n![](https://s28.q4cdn.com/169506891/files/images/management/John-Westman.jpg)\n\nJohn Westman has led commercial efforts—including strategy, sales management, marketing, business development, customer service and strategic partnerships—resulting in improved business results for market-leading and start-up healthcare companies. Prior positions include co-founder and Executive Vice President of Novellus, Inc., General Manager and Vice President of Marketing and Sales for PrecisionMD, NxStage, Fresenius, PharMetrics and Decision Resources Pharmaceutical. John led U.S. and global marketing and sales training at Baxter Healthcare’s Renal division and started his career at Bain Consulting/Baxter consulting firm. John is a Fulbright Scholar who received a B.A. in French and English from Colgate, an M.A. in international relations from the University of Wisconsin, and an MBA in marketing and finance from the Kellogg Graduate School of Management at Northwestern. John is on the faculty at Harvard and Boston College.\n\n#### \n\nPaul SowyrdaVP, Business Development & Market Intelligence\n\n![](https://s28.q4cdn.com/169506891/files/images/management/Paul-Sowyrda.jpg)\n\nPaul Sowyrda is a seasoned Biopharmaceutical leader and inventor with over 25 years of experience helping to build and lead development stage and commercial companies. He is co-founder of Novellus, Inc. which was sold to Brooklyn ImmunoTherapeutics, Inc. in July 2021, and served as its Executive Vice President. Mr. Sowyrda held previous positions as Vice President of Drug Development at CIBA, and Vice President of Development and Marketing at Dusa Pharmaceuticals, which was acquired by Sun Pharma. Mr. Sowyrda is an inventor and holds more than 15 patents, He has served on the Board of Directors for the Society of Concurrent Product Development and is a member of the American Academy of Dermatology and International Society of Dermatologic Surgery. He earned his B.S. and M.S. from the University of Notre Dame, his MBA from Babson College, and completed the MIT Sloan School of Management Senior Executives Program.\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Board of Directors",
          "url": "https://citiuspharma.com/about/board-of-directors/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Board of Directors\n\n**Board Diversity Matrix (as of December 31, 2023)**\n\nTotal Number of Directors | 6  \n---|---  \nFemale | Male | Non-Binary | Did Not disclose Gender  \nPart I: Gender Identity  \nDirectors | 1 | 5 | - | -  \nPart II: Demographic Background  \nAfrican American or Black | - | - | - | -  \nAlaskan Native or Native American | - | - | - | -  \nAsian | - | 1 | - | -  \nHispanic or Latinx | - | - | - | -  \nNative Hawaiian or Pacific Islander | - | - | - | -  \nWhite | 1 | 4 | - | -  \nTwo or More Races or Ethnicities | - | - | - | -  \nLGBTQ+ | - | - | - | -  \nDid Not Disclose Demographic Background | - | - | - | -  \n  \n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Committee Composition",
          "url": "https://citiuspharma.com/investors/governance/committee-composition/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Committee Composition\n\nAudit Committee  |  Compensation Committee  |  Nominating and Corporate Governance Committee   \n---|---|---  \nLeonard Mazur  \nMyron Holubiak  \nSuren Dutia  \nEugene Holuka, MD  \nCarol Webb  \nDennis M. McGrath  \n  \n#### \n\nAudit Committee\n\nSuren Dutia\n\nCarol Webb\n\nDennis M. McGrath\n\n#### \n\nCompensation Committee\n\nEugene Holuka, MD\n\nCarol Webb\n\n#### \n\nNominating and Corporate Governance Committee\n\nEugene Holuka, MD\n\nCarol Webb\n\nDennis M. McGrath\n\n  * Board Chair\n  * Committee Member\n  * Committee Chair\n\n\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Governance Documents",
          "url": "https://citiuspharma.com/investors/governance/governance-documents/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Governance Documents\n\nDownload item year list\n\nDownload Description\n\n[ Audit and Risk Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Audit_Committee_Charter.pdf)\n\n96 KB\n\n[ Compensation Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/2022/08/Compensation-Committee-Charter-2022-\\(1\\).pdf)\n\n83 KB\n\n[ Nominating and Governance Committee Charter PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Nom__Gov_Committee_Charter.pdf)\n\n74 KB\n\n[ Corporate Communications Policy PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Corporate_Communications_Policy.pdf)\n\n89 KB\n\n[ Insider Trading Policy PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Insider_Trading_Policy.pdf)\n\n108 KB\n\n[ Code of Ethics PDF Format (opens in new window) ](//s28.q4cdn.com/169506891/files/doc_downloads/governance/Code_of_Ethics.pdf)\n\n79 KB\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor FAQs\n\nDisplay All\n\n#### \n\nWhat is Citius Pharmaceuticals, Inc.'s ticker symbol?\n\nCTXR\n\n#### \n\nWhere is Citius Pharmaceuticals, Inc. stock traded?\n\nOur stock is traded on the Nasdaq exchange.\n\n#### \n\nWhen was Citius Pharmaceuticals, Inc. incorporated?\n\n2010\n\n#### \n\nWhen did Citius Pharmaceuticals, Inc. become a public company?\n\nSeptember 2014\n\n#### \n\nWhere is Citius Pharmaceuticals, Inc. located?\n\n11 Commerce Drive, First Floor Cranford, NJ 07016\n\n#### \n\nWhen is Citius Pharmaceuticals, Inc.'s fiscal year end?\n\nSeptember 30th\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s transfer agent?\n\nVStock Transfer LLC 18 Lafayette Place Woodmere, NY 11598 T: [212-828-8436](tel:212-828-8436) [www.vstocktransfer.com](http://www.vstocktransfer.com)\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s independent auditor?\n\nWolf & Company, P.C. 99 High Street Boston, MA 02110\n\n#### \n\nWho is Citius Pharmaceuticals, Inc.'s outside legal counsel?\n\nWyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail Suite 300 Raleigh, NC 27607 [www.wyrick.com](http://www.wyrick.com)\n\n#### \n\nWhen did Citius acquire Leonard Meron Biosciences (LMB)?\n\nOn March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary. The Company acquired all of the outstanding stock of LMB by issuing shares of its common stock.\n\n#### \n\nWhom can I contact for general information about Citius Pharmaceuticals, Inc.?\n\nCitius Pharmaceuticals, Inc. Tel: [(908) 967-6677](tel:\\(908\\) 967-6677) Email: info@citiuspharma.com\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Information Request Form",
          "url": "https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Information Request Form\n\nThe following errors must be corrected\n\n• First Name is required\n\n• Last Name is required\n\n• Company Name is required\n\n• Email Address is required\n\n• Phone Number is required\n\n• State/ Province is required\n\n• Country is required\n\n• Information Request is required\n\n• Are you an investor? is required\n\nFirst Name*\n\nLast Name*\n\nCompany Name*\n\nEmail Address*\n\nPhone Number*\n\nState/ Province*\n\nCountry*AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurmaBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongo (Brazzaville)Congo (Kinshasa)Costa RicaCôte d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMoroccoNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorth KoreaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint LuciaSaint Vincent and the GrenadinesSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSeychellesSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth KoreaSpainSri LankaSt. Kits and NevisSudanSurinameSwazilandSwedenSwitzerlandSyriaTajikistanTanzaniaThailandThe BahamasTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamWestern SamoaYemenZaireZambiaZimbabwe\n\nInformation Request*\n\nAre you an investor?*\n\n  * I am an investor\n  * I am not an investor\n\n\n\nSubmit\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Investor Email Alerts",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-email-alerts/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor Email Alerts\n\n## Subscribe To Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\nFor further information on how we protect your information, please refer to our [Disclaimer](/privacy-policy/default.aspx).\n\n## Unsubscribe From Investor Email Alerts\n\nTo opt-out of investor email alerts, please enter your email address in the field below and you will be removed from all investor relations email alerts to which you are subscribed. After submitting your email, you will receive a confirmation email to the requested email address. You must click the confirmation link in order to complete your request to unsubscribe. You can elect to receive investor alerts at any time you would like.\n\n* Required\n\nEmail Address *  \n---  \n  \nUnsubscribe\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        },
        {
          "title": "Investor Contacts",
          "url": "https://citiuspharma.com/investors/investor-resources/investor-contacts/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[ ![Citius Pharma Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-logo-wide.png) ](https://www.citiuspharma.com/)\n\n### [We support Ukraine](/Ukraine)\n\n# Investor Contacts\n\n###  Investor Relations \n\nIlanit Allen VP of Corporate Communications & Investor Relations [ 908-967-6677 ext. 113 ](tel:908-967-6677) ir@citiuspharma.com\n\n###  Transfer Agent \n\nVStock Transfer LLC 18 Lafayette Place Woodmere, NY 11598 [ 212-828-8436 ](tel:212-828-8436) [www.vstocktransfer.com](https://www.vstocktransfer.com)\n\n###  Auditor \n\nWolf & Company, P.C. 99 High Street Boston, MA 02110\n\n###  Legal Counsel \n\nWyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail Suite 300 Raleigh, NC 27607 [www.wyrick.com](https://www.wyrick.com)\n\n### Contact Us\n\nCitius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 \n\n[908-967-6677](tel:908-967-6677) info@citiuspharma.com\n\n  * [follow us on twitter](https://twitter.com/CitiusPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor)\n  * [follow us on linkedin](https://www.linkedin.com/company/citius-pharmaceuticals-inc)\n\n\n\n### Quick Links\n\n  * [SEC Filings](https://citiuspharma.com/investors/financials/sec-filings/default.aspx)\n  * [Investor FAQs](https://citiuspharma.com/investors/investor-resources/investor-faqs/default.aspx)\n  * [Information Request Form](https://citiuspharma.com/investors/investor-resources/information-request-form/default.aspx)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Citius Pharmaceuticals, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/investor-resources/investor-email-alerts)\n\n## Email Alert Sign Up Confirmation\n\n[ REQUEST A MEETING WITH MANAGEMENT ](javascript:; \"Request a meeting with management\")\n\n[![Citius Pharmaceuticals Logo](//s28.q4cdn.com/169506891/files/design/assets/citius-pharma-white-logo-wide.png)](https://www.citiuspharma.com/)\n\n  * [Disclaimer](https://citiuspharma.com/privacy-policy/default.aspx)\n  * [Terms of Use](https://citiuspharma.com/terms-of-use/default.aspx)\n\n\n\n© 2024 Citius Pharmaceuticals, Inc. - All rights reserved \n"
        }
      ]
    }
  ]
}